{"transactions":[{"id":1210318,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2025-03-12T20:31:26.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":false,"shares":2222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"exercise_date":"2025-03-10","underlying":"Common Stock","underlying_shares":2222000},"source":{"system":"sec-edgar","filing":"0001578563-25-000173","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856325000173/primary_doc.xml","form_type":"4"}},{"id":1210317,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-03-12T20:31:26.000Z","date":"2025-03-10","kind":"exercise","planned":false,"acquired":true,"shares":2222000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") automatically converted into 1,000 shares of the Issuer's common stock on the first trading day following the announcement of the Issuer's stockholders approval of the issuance of the Issuer's common stock upon conversion of the shares of Series A, which such announcement occurred on March 7, 2025."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2809848,"source":{"system":"sec-edgar","filing":"0001578563-25-000173","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856325000173/primary_doc.xml","form_type":"4"}},{"id":1336212,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2024-12-11T19:38:16.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":3333000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The warrant becomes exercisable once the Issuer's stockholders first approve the issuance of the Issuer's common stock underlying the warrants in excess of the limitations imposed by Rule 5635 of the Nasdaq Stock Market listing rules."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":3330000,"derivative":{"exercise_price":2.3,"expiration_date":"2029-12-09","underlying":"Common Stock","underlying_shares":3333000},"source":{"system":"sec-edgar","filing":"0001578563-24-000493","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000493/primary_doc.xml","form_type":"4"}},{"id":1336211,"issuer":{"id":7935,"kind":"organization","name":"Senti Biosciences Holdings, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2024-12-11T19:38:16.000Z","date":"2024-12-09","kind":"purchase","planned":false,"acquired":true,"shares":2222,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported securities include shares of Series A and warrants purchased by the reporting person for $2,250 per unit. Each unit consists of one share of Series A, convertible into 1,000 shares of the Issuer's common stock, and accompanying warrant coverage to purchase 1,500 shares of the Issuer's common stock for each share of Series A purchased."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each share of Series A Convertible Preferred Stock (\"Series A\") will convert into 1,000 shares of the Issuer's common stock upon the date that the Issuer's stockholders first approve the issuance of the Issuer's common stock upon conversion of the shares of Series A."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is indirectly controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2222,"derivative":{"underlying":"Common Stock","underlying_shares":2222000},"source":{"system":"sec-edgar","filing":"0001578563-24-000493","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000493/primary_doc.xml","form_type":"4"}},{"id":1641383,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":890671,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":509855},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641382,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":1030086,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":589662},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641381,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-4 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":2062387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1180592},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641380,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":false,"shares":3093580,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1770888},"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641379,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":509855,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":4050997,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641378,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":589662,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":3541142,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641377,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1180592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of Series A-4 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's IPO."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":2951480,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1641376,"issuer":{"id":7270,"kind":"organization","name":"Metagenomi Therapeutics, Inc.","symbol":"MGX"},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-02-15T17:59:01.000Z","date":"2024-02-13","kind":"exercise","planned":false,"acquired":true,"shares":1770888,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Convertible Preferred Stock automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's Initial Public Offering (\"IPO\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1770888,"source":{"system":"sec-edgar","filing":"0001578563-24-000080","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856324000080/primary_doc.xml","form_type":"4"}},{"id":1824314,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":false,"shares":1307401,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1307401},"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}},{"id":1824313,"issuer":{"id":7959,"kind":"organization","name":"Azitra, Inc."},"owners":[{"id":82086,"kind":"organization","name":"BAYER HEALTHCARE LLC","position":1,"cik":"0001231517","reported_name":"BAYER HEALTHCARE LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82087,"kind":"organization","name":"Bayer US Holding LP","position":2,"cik":"0001965754","reported_name":"Bayer US Holding LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82088,"kind":"organization","name":"Bayer World Investments B.V.","position":3,"cik":"0001820027","reported_name":"Bayer World Investments B.V.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":82089,"kind":"person","name":"BAYER AKTIENGESELLSCHAFT","position":4,"cik":"0001144145","reported_name":"BAYER AKTIENGESELLSCHAFT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-07-24T17:51:04.000Z","date":"2023-06-21","kind":"exercise","planned":false,"acquired":true,"shares":1307401,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Convertible Preferred Stock automatically converted into shares of common stock of the Issuer upon the closing of the Issuer's IPO at a conversion price equal to approximately $1.11 per share, after making certain anti-dilution adjustments. The Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The securities reported are held directly by Bayer HealthCare LLC, a Delaware limited liability company, which is controlled by Bayer US Holding LP (\"BUSH LP\"), a Delaware limited partnership.  Bayer World Investments B.V. (\"BWI\"), a Dutch private limited company, is the general partner of BUSH LP.  BWI is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a publicly-held German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer HealthCare LLC."}],"balance_after":1307401,"source":{"system":"sec-edgar","filing":"0001578563-23-000065","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1144145/000157856323000065/primary_doc.xml","form_type":"4"}}]}